In this issue:
PPIs reduce survival in advanced lung cancer treated with TKIs
Segmentectomy vs. lobectomy in small-sized peripheral NSCLC
5-year survival with durvalumab after chemo-RT in stage III NSCLC
Second-line liposomal irinotecan in SCLC
Lorlatinib for advanced ALK-positive NSCLC
First-line nivolumab + ipilimumab in unresectable malignant pleural mesothelioma
PD-(L)1 inhibitors alone or with chemotherapy in nonsquamous PDL1- high NSCLC
Postoperative adjuvant chemotherapy for elderly NSCLC
Adding single-site RT to PD-1 inhibitors in oligometastatic NSCLC
Carboplatin + nab-paclitaxel for advanced NSCLC with interstitial lung disease
Please login below to download this issue (PDF)